

S/14/09

JF 1645

Please type a plus sign (+) inside this box

+

PTO/SB/21 (05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL FORM</b>  (to be used for all correspondence after initial filing)		Application Number	09/917,222
		Filing Date	July 27, 2001
		First Named Inventor	GRANOFF, DAN M.
		Group Art Unit	1645
		Examiner Name	ZEMAN, ROBERT A.
Total Number of Pages in This Submission	7	Attorney Docket Number	CHOR-001
<b>ENCLOSURES (check all that apply)</b>			
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):  40 References  Postcard
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences	
<input type="checkbox"/> Amendment / Reply	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)	
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition	<input type="checkbox"/> Proprietary Information	
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter	
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address		
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer		
<input checked="" type="checkbox"/> Copy of Information Disclosure Statement and SB/08A filed on April 22, 2002	<input type="checkbox"/> Request for Refund		
<input type="checkbox"/> Certified Copy of Priority Documents	<input type="checkbox"/> CD, Number of CD(s)		
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application	Remarks		
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53			
<b>SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT</b>			
Signing Attorney/Agent (Reg. No.)	CAROL L. FRANCIS, 36,513 BOZICEVIC, FIELD & FRANCIS LLP		
Signature			
Date	May 12, 2004		

EXPRESS MAIL NO. EV 333997834 US

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

EXPRESS MAIL NO. EV 333997834 US

**COMMUNICATION**

Address to:  
Mail Stop  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Customer Number	24353
Atty. Docket No.	CHOR-001
Application Number	09/917,222
Confirmation Number	9605
Filing Date	July 27, 2001
First Named Inventor	GRANOFF, DAN M.
Examiner Name	ZEMAN, ROBERT A.
Group Art Unit	1645

Sir:

An Information Disclosure Statement (IDS) was filed on April 22, 2002. The IDS included a PTO Form SB/08A citing both patent and non-patent references.

In a teleconference with Examiner Zeman, the undersigned was advised that the non-patent references had not been matched with the file and were apparently lost.

Applicants provide with this Communication a copy of the IDS as filed, along with copies of the non-patent references. The Examiner is requested to consider all references cited in the PTO Form SB/08A included herewith, and indicate such consideration by placing his initials next to each cited reference, and return a copy of the initialed Form with the next action.

Because the IDS was originally filed before the receipt of the first Office Action on the merits, no additional fee is believed to be due. However, the Commissioner is hereby authorized to charge any fees associated with this communication, or credit any overpayment to Deposit Account No. 50-0815, order number CHOR-001.

Respectfully submitted,  
BOZICEVIC, FIELD & FRANCIS LLP

Date:

*May 12, 2004*

By:

*Carol L. Francis*  
Carol L. Francis  
Registration No. 36,513

BOZICEVIC, FIELD & FRANCIS LLP  
200 Middlefield Road, Suite 200  
Menlo Park, CA 94025  
Telephone: (650) 327-3400  
Facsimile: (650) 327-3231

Please type a plus sign (+) inside this box

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>		<b>Complete if Known</b>	
		Application Number	09/917,222
		Filing Date	July 27, 2001
		First Named Inventor	Granoff et al.
		Group Art Unit	1645
		Examiner Name	N/A
Sheet 1 of 4	Attorney Docket Number	CHOR-001	

U.S. PATENT DOCUMENTS						
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	U.S. Patent Documents		Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, columns, lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
	AA	4,601,903		Frasch	07-22-1986	
	AB	4,727,136		Jennings, et al.	02-23-1988	
	AC	5,705,161		Van Der Ley et al.	01-06-1998	

FOREIGN PATENT DOCUMENTS								
Examiner Initials'	Cite No.¹	Foreign Patent Documents			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T²
		Office³	Number⁴	Kind Code⁵ (if known)				
	AD		0 449 958 B1		Seid et al.	03/22/95		
	AE		WO 00/22430		Frazer et al.	04/20/00	(See CD-ROM)	
	AF		WO 00/66791		Pizza et al.	02/09/00	(See CD-ROM)	
	AG		WO 01/09350		Berthet et al.	02/08/01		
	AH		WO 96/29412		Brodeur et al.	09/26/96		
	AI		WO 98/02547		Nassif et al.	01/22/98		
	AJ		WO 98/56901		Baldwin et al.	12/17/98		
	AK		WO 99/24578		Masignani et al.	05/20/99	(See CD-ROM)	
	AL		WO 99/36544		Masignani et al.	07/22/99		
	AM		WO 99/57280		Fraser et al.	04/30/99	(See CD-ROM)	
	AN		WO 99/61053		Granoff et al.	12/02/99		



Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995 (44 USC 3506(c)(2)), no person is required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		<b>Complete if Known</b>	
		<b>Application Number</b>	<b>09/917,222</b>
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		<b>Filing Date</b>	<b>July 27, 2001</b>
		<b>First Named Inventor</b>	<b>Granoff et al.</b>
		<b>Group Art Unit</b>	<b>1645</b>
		<b>Examiner Name</b>	<b>N/A</b>
		<b>Attorney Docket Number</b>	<b>CHOR-001</b>
(use as many sheets as necessary)			
Sheet	2	of	4

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	AO	ASHTON, F. E. et al., 1938, "A New Serogroup (L) of <i>Neisseria meningitidis</i> ", <i>J. Clin. Microbiol.</i> 17: 722-727.	
	AP	BORROW, et al., 2001, "Serological Basis for Use of Meningococcal Serogroup C Conjugate Vaccines in the U.K.: Reevaluation of Correlates of Protection", <i>Infection and Immunity</i> , 69(3):1568-1573.	
	AQ	BRANHAM, S. E., 1956, "Milestones in the History of Meningococcus", <i>Canadian Journal of Microbiology</i> , 2:175-188.	
	AR	CAMPAGNE et al. 2000, "Safety and immunogenicity of three doses of a <i>Neisseria meningitidis</i> A + C diphtheria conjugate vaccine in infants from Niger", <i>Pediatric Infectious Disease Journal</i> , 19(2):144-150.	
	AS	CARTWRIGHT K et al, 1999, "Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins", <i>Vaccine</i> , 17:2612-2619.	
	AT	DE KLEINJN ED et al, 2000, "Immunogenicity and safety of a hexavalent meningococcal outer membrane-vesicle vaccine in children of 2-3 and 7-8 years of age", <i>Vaccine</i> , 18:1456-1466.	
	AU	FRASCH, C. E. AND CHAPMAN, 1973, "Classification of <i>Neisseria meningitidis</i> Group B into Distinct Serotypes. III. Application of a New Bactericidal-Inhibition Technique to Distribution of Serotypes among Cases and Carriers" <i>Journal of Infectious Disease</i> , 127:149-154.	
	AV	FUSCO et al., 1997, "Preclinical Evaluation of a Novel Group B Meningococcal Conjugate Vaccine that Elicits Bactericidal Activity in both Mice and Nonhuman Primates", <i>Journal of Infectious Diseases</i> , 175: 364-372.	
	AW	GOLD et al., 1969-1970, "Meningococcal Infections" <i>Bull. WHO</i> , 45: 272-282.	
	AX	GOLDSCHNEIDER et al, 1969, "Human Immunity to the Meningococcus: I. The Role of the Humoral Antibodies" <i>J. Exp. Med.</i> 129:1307-1326.	
	AY	GOTSCHLICH et al., 1969, "Human Immunity to the Meningococcus: III. Preparation and Immunochemical Properties of the Group A, Group B, and Group C Meningococcal Polysaccharides", <i>J. Exp. Med.</i> 129:134-136.	
	AZ	GRANOFF et al., 1998, "Bacterial Monoclonal Antibodies That Define Unique Meningococcal B Polysaccharide Epitopes That Do Not Cross-React with Human Polysialic Acid", <i>J. Immunol.</i> 160: 5028-5036.	
	BA	GRANOFF et al., 1998, "Induction of Immunologic Refractoriness in Adults by Meningococcal C Polysaccharide Vaccination", <i>J. Infect. Dis.</i> 178(3): 870-4.	



Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		<b>Complete if Known</b>	
		<b>Application Number</b>	09/917,222
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		<b>Filing Date</b>	July 27, 2001
		<b>First Named Inventor</b>	Granoff et al.
		<b>Group Art Unit</b>	1645
		<b>Examiner Name</b>	N/A
		<b>Attorney Docket Number</b>	CHOR-001
(use as many sheets as necessary)			
Sheet	3	of	4

BB	HANKINS, 1982, "Clinical and Serological Evaluation of a Meningococcal Polysaccharide Vaccine Groups A,C,Y, and W135 (41306), <i>Proc. Soc. Biol. Med.</i> 169: 54-57.
BC	HONG et al., 1981, "Inhibitory Effect of K-76 Monocarboxylic Acid, an Anticomplementary Agent, on the C3b Inactivator System" <i>J Immunol.</i> 127:104-108
BD	MACDONALD et al., 1998, "Induction of Immunologic Memory by Conjugated vs Plain Meningococcal C Polysaccharide Vaccine in Toddlers", <i>JAMA</i> 280:1685-1689
BE	MACDONALD et al., 2000, "Can Meningococcal C Conjugate Vaccine Overcome Immune Hyporesponsiveness Induced by Previous Administration of Plain Polysaccharide Vaccine?" <i>JAMA</i> 283:1826-1827
BF	MACLENNAN et al., 2000, "Safety, Immunogenicity, and Induction of Immunologic memory by a Serogroup C Meningococcal Conjugate Vaccine in Infants" <i>JAMA</i> 283: 2795-2801
BG	MAIDEN et al., 1998, "Multilocus sequence typing: A portable approach to the identification of clones within populations of pathogenic microorganisms", <i>Proc. Natl. Acad. Sci. USA</i> 95:3140-3145.
BH	MARTIN et al., 2000. "Candidate <i>Neisseria meningitidis</i> NspA vaccine", <i>J. Biotechnol.</i> 83:27-31
BI	MARTIN et al, 2000, "Effect of sequence variation in meningococcal PorA outer membrane protein on the effectiveness of a hexavalent PorA outer membrane vesicle vaccine", <i>Vaccine</i> , 18:2476-2481
BJ	MOE et al. 1999, "Differences in Surface Expression of NspA among <i>Neisseria meningitidis</i> Group B Strains", <i>Infection and Immunity</i> , 67:5664-5675.
BK	MOE et al. 2001, "Functional Activity of Anti-Neisserial Surface Protein A Monoclonal Antibodies against Strains of <i>Neisseria meningitidis</i> Serogroup B", <i>Infection and Immunity</i> , 69:3762-3771.
BL	MILAGRES et al., 1994, " Immune Response of Brazilian Children to a <i>Neisseria meningitidis</i> Serogroup B Outer Membrane Protein Vaccine; Comparison with Efficacy", <i>Infection and Immunity</i> , 62: 4419-4424.
BM	PIZZA et al. 2000 "Identification of Vaccine Candidates Against Serogroup B <i>Meningococcus</i> by Whole-Genome Sequencing", <i>Science</i> 287:1816-1820.
BN	ROUPPE VAN DER VOORT et al., 2000, "Immunogenicity studies with a genetically engineered hexavalent PorA and a wild-type meningococcal group B outer membrane vesicle vaccine in infant cynomolgus monkeys", <i>Vaccine</i> , 18:1334-1343.
BO	SACCHI et al., 1998, "Correlation between Serological and Sequencing Analyses of the PorB Outer Membrane Protein in the <i>Neisseria meningitidis</i> Serotyping System", <i>Clin. Diag. Lab. Immunol.</i> 5:348-354.
BP	SACCHI et al., 2000, "Diversity and Prevalence of PorA Types in <i>Neisseria meningitidis</i> Serogroup B in the United States", <i>Journal of Infectious Diseases</i> , 182:1169-1176.


Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	09/917.222
		Filing Date	July 27, 2001
		First Named Inventor	Granoff et al.
		Group Art Unit	1645
		Examiner Name	N/A
Sheet 4 of 4	Attorney Docket Number	CHOR-001	

BQ	SAUKKONEN et al. 1988, "Monoclonal Antibodies to the Rough Lipopolysaccharide of <i>Neisseria meningitidis</i> Protect Infant Rats From Meningococcal Infection" <i>Journal of Infectious Diseases</i> , 158: 209-212.	
BR	SHAO-QING, et al., 1981, "Three new serogroups of <i>Neisseria meningitidis</i> ", <i>J. Biol. Stand.</i> 9: 307-315.	
BS	SLATERUS, K. W., 1961, Ant. V. Leeuwenhoek, "Types of Meningococcal Isolated from Carriers and Patients in a Non-Epidemic Period in the Netherlands", <i>J. Microbiol. Serol.</i> 29: 265-271	
BT	STEPHENS et al. 1991, "Insertion of Tn916 in <i>Neisseria meningitidis</i> Resulting in Loss of Group B Capsular Polysaccharide", <i>Infection and Immunity</i> , 59: 4097-4107	
BU	TAPPERO et al., 1999, "Immunogenicity of 2 Serogroup B Outer-Membrane Protein Meningococcal Vaccines", <i>JAMA</i> 281:1520-1572.	
BV	WYLE et al., 1972, "Immunologic Response of Man to Group B Meningococcal Polysaccharide Vaccines", <i>J Infect. Dis.</i> 126: 514-522.	
BW	ZOLLINGER, et al., 1979, "Complex of Meningococcal Group B Polysaccharide and Type 2 Outer Membrane Protein Immunogenic in Man", <i>J Clin. Invest.</i> 63: 836-848.	
BX	NAESS, et al. 1998, "Human T-Cell Response after Vaccination with the Norwegian Group B Meningococcal Outer Membrane Vesicle Vaccine" <i>Infection and Immunity</i> , Vol. 66(3): 959-965.	
BY	HANEBERG et al. 1998, "Intranasal Administration of a Meningococcal Outer Membrane Vesicle Vaccine Induces Persistent Local Mucosal Antibodies and Serum Antibodies with Strong Bactericidal Activity in Humans", <i>Infection and Immunity</i> , Vol. 66(4): 1334-1341.	
BZ	WEDEGE et al. 1998, "Immune Response against Major Outer Membrane Antigens of <i>Neisseria meningitidis</i> in Vaccines and Controls Contracted Meningococcal Disease during the Norwegian Serogroup B Protection Trail", <i>Infection and Immunity</i> , Vol. 66(7): 3223-3231.	
CA	LEHMANN et al. 1999, "Human Opsonins Induced during Meningococcal Disease Recognize Outer Membrane Proteins PorA and PorB", <i>Infection and Immunity</i> , Vol. 67(5):2552-2560.	
CB	ROSENQVIST et al. "Human Antibody Responses to Meningococcal Outer Membrane Antigens after three Doses of the Norwegian Group B Meningococcal Vaccine", <i>Infection and Immunity</i> , Vol. 63(12): 46-42-4652.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.